Edgewise Therapeutics, Inc.
EWTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Edgewise Therapeutics, Inc. (EWTX) is listed under Biotechnology. The $3.68B market capitalization puts EWTX squarely in mid-cap range for its industry. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Market Cap
$3.68B
Beta
0.25
P/E (TTM)
—
P/E (Fwd)
-14.65
EPS (TTM)
$-1.66
EPS (Fwd)
$-2.33
ROE
-38.1%
ROA
-25.6%
Cash
$499.6M
Total Debt
$3.8M
Free CF
-$90.5M
52W Change
132.5%
Annual Financials
Cash vs Debt
With $499.6M in cash and $3.8M in debt, EWTX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$90.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -38.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, Edgewise Therapeutics, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Edgewise Therapeutics, Inc.'s trajectory.